Kansas is currently home to 886 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Wichita, Kansas City, Overland Park and Topeka. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease
NCT06409130
Recruiting
The study will look at the effects of NNC0194-0499, cagrilintide and semaglutide, on liver damage and alcohol use in participants with alcoholic liver disease. Participants will get NNC0194-0499, semaglutide, cagrilintide or ''dummy" medicine in different treatment combinations. Which treatment participants get is decided by chance. The study will last for about 39 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: Kansas Medical Clinic, PA, Topeka, Kansas
Conditions: Alcohol-related Liver Disease
Register for Updates
A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
NCT05785624
Recruiting
The main purpose of the study is to evaluate the efficacy of vixarelimab compared with placebo on lung function in participants with idiopathic pulmonary fibrosis (IPF) and in participants with systemic sclerosis-associated interstitial lung disease (SSc-ILD). Participants who complete 52-weeks of treatment in the Double-blind Treatment (DBT) period can choose to enroll in the optional Open-label Extension (OLE) period to receive treatment with vixarelimab for another 52 weeks. Cohort 1 has com... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
04/14/2025
Locations: University of Kansas Medical Center, Kansas City, Kansas
Conditions: Idiopathic Pulmonary Fibrosis, Systemic Sclerosis With Lung Involvement
Register for Updates
Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)
NCT05571059
Recruiting
Ifetroban prevents and treats lung fibrosis due to multiple causes (bleomycin, genetic, radiation). The safety and efficacy of oral ifetroban will be assessed in patients with IPF.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
04/14/2025
Locations: University of Kansas, Kansas City, Kansas
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma
NCT00904241
Recruiting
This research trial studies biomarkers in tumor tissue samples from patients with newly diagnosed neuroblastoma or ganglioneuroblastoma. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
Gender:
ALL
Ages:
30 years and below
Trial Updated:
04/14/2025
Locations: University of Kansas Cancer Center, Kansas City, Kansas
Conditions: Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
Register for Updates
Global Study of Del-desiran for the Treatment of DM1
NCT06411288
Recruiting
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Global Study to Evaluate the Efficacy and Safety of Intravenous Delpacibart Etedesiran (abbreviated del-desiran, formerly AOC 1001) for the Treatment of Myotonic Dystrophy Type 1
Gender:
ALL
Ages:
Between 16 years and 65 years
Trial Updated:
04/11/2025
Locations: Kansas University Medical Center, Kansas City, Kansas
Conditions: DM1, Myotonic Dystrophy, Myotonic Dystrophy 1, Myotonia, Myotonic Dystrophy Type 1 (DM1), Dystrophy Myotonic, Myotonic Disorders, Steinert Disease, Steinert, Myotonic Muscular Dystrophy
Register for Updates
Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back Pain
NCT06325566
Recruiting
The primary purpose of this study is to evaluate the efficacy of rexlemestrocel-L+HA compared to control in reducing low back pain at 12 months post-treatment and safety of a single injection of rexlemestrocel-L+HA injected into a lumbar intervertebral disc compared to control through 12 months post-treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/11/2025
Locations: University of Kansas Medical Center, Kansas City, Kansas
Conditions: Degenerative Disc Disease
Register for Updates
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
NCT06268873
Recruiting
The purpose of this study is to measure the efficacy and safety of baxdrostat/dapagliflozin in participants ≥ 18 years of age with CKD and HTN. This study consists of a screening, a 4-week dapagliflozin run-in period for participants naïve to SGLT2i at baseline; a 24-month double-blind period in which participants will receive either baxdrostat/dapagliflozin or dapagliflozin; and a 6-week open-label period in which all participants will discontinue baxdrostat/placebo and receive dapagliflozin a... Read More
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
04/11/2025
Locations: Research Site, Hutchinson, Kansas
Conditions: Chronic Kidney Disease and Hypertension
Register for Updates
Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome
NCT05419011
Recruiting
This phase IIb trial tests whether Tri-Ad5 in combination with N-803 works to prevent colon and other cancers in participants with Lynch syndrome. Each of the three injections in Tri-Ad5 vaccine contain a different substance that is in precancer and cancer cells. Injecting these substances may cause the immune system to develop a defense against cancer that recognizes and destroys any precancer and cancer cells that produce these proteins in the future. N-803 may increase immune responses to oth... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/11/2025
Locations: University of Kansas Cancer Center, Kansas City, Kansas
Conditions: Lynch Syndrome, Colorectal Carcinoma
Register for Updates
Liposomal Bupivacaine Versus Lidocaine for Skin Graft Donor Site Pain
NCT03854344
Recruiting
Donor site pain study comparing post-operative donor site pain and opioid consumption after use of Lidocaine, Liposomal Bupivicaine or regional nerve block for split thickness skin graft harvesting in patients with less than 20% TBSA burn wounds and less than %5 Deep partial or full thickness burn wounds.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/11/2025
Locations: The University of Kansas Health System, Kansas City, Kansas
Conditions: Pain, Postoperative, Burns
Register for Updates
Quantify the Degree of Pain Relief of Pelvic Congestion Syndrome Following Gonadal Vein Embolization
NCT03794466
Recruiting
The primary objective is to quantify the degree of pain relief in patients undergoing gonadal vein embolization with coils as well as identify clinical or imaging factors that are predictive of a positive response to treatment, or poor response to treatment.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/11/2025
Locations: The University of Kansas Medical Center, Kansas City, Kansas
Conditions: Pelvic Congestive Syndrome, Pelvic Pain
Register for Updates
Mevrometostat Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
NCT03460977
Recruiting
A Phase 1 Dose Escalation and Expanded Cohort Study Of PF-06821497 (Mevrometostat) in Adult Patients With Relapsed/Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) And Follicular Lymphoma (FL).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/11/2025
Locations: The University of Kansas Cancer Center, Investigational Drug Services, Fairway, Kansas
Conditions: Small Cell Lung Cancer (SCLC), Follicular Lymphoma (FL), Metastatic Castration Resistant Prostate Cancer (mCRPC)
Register for Updates
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
NCT03435796
Recruiting
This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T-cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study. Participants who received at least one infusion of GM T cells will be asked to enroll in this LTFU protocol upon either premature discontinuation from, or completion of the prior parent treatment protocol.
Gender:
ALL
Ages:
All
Trial Updated:
04/11/2025
Locations: Kansas University Medical Center, Westwood, Kansas
Conditions: Neoplasms
Register for Updates